SGP today reported that it has completed patient enrollment in the boceprevir HCV SPRINT-2 study. The Company expects to complete the drug studies in mid-2010. <a href="http://finance.yahoo.com/news/ScheringPlough-Completes-prnews-14163460.html" target="_blank">http://finance.yahoo.com/news/ScheringPlough-Completes-prnews-14163460.html</a>